The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

September 6, 2007

Last Updated Date

September 6, 2007

Start Date ^†

January 2007

Current Primary Outcome Measures ^†

Weight change [ Time Frame: 10 weeks ]

Original Primary Outcome Measures ^†

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^†

Blood lipids Body fat Fasting blood glucose [ Time Frame: 10 weeks ]

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

Official Title ^†

The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Brief Summary

Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.

Detailed Description

To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.

The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group): Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).

The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks. No major dietary changes or exercises were suggested during the study.

Study Phase

Study Type ^†

Interventional

Study Design ^†

Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study

Condition ^†

Obesity
Overweight
Dyslipidemia

Intervention ^†

Dietary Supplement: Irvingia/cissus combo

Study Arms / Comparison Groups

Active Comparator: Comparison of actives for synergy

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

April 2007

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

BMI>26kg/m2

Exclusion Criteria:

Diabetics
Pregnant and lactating
Subjects on any other weight loss program
Following any specific low calorie diet

Gender

Both

Ages

19 Years to 55 Years

Accepts Healthy Volunteers

Yes

Contacts ^††

Location Countries ^†

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00526682

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Gateway Health Alliance

Collaborators ^††

Investigators ^†

Principal Investigator:

Julius E OBEN, PhD

University of Yaounde I, Cameroon

Information Provided By

Gateway Health Alliance

Verification Date

September 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.